UC San Diego

This study investigates the role of tert-Butylhydroquinone (tBHQ) and steroids inregulating IL17D expression in fibroblasts, fibrosarcoma cell lines, and melanoma, alongside examining IL17D's influence on fibroblast migration, macrophage antigen presentation, and the presence of TGF-beta 1 protein in fibroblast supernatant. My findings reveal a differential induction of IL17D across cell types and treatment conditions. Specifically, tBHQ significantly induces IL17D in primary fibroblasts but not in fibrosarcoma or melanoma cells, where hydrocortisone instead prompts IL17D expression. This suggests a context-dependent regulation of IL17D, potentially impacting disease progression or treatment responses.

Further, IL17D enhances migration in both fibroblasts and D29M1 fibrosarcomacells, suggesting a role of IL17D in cell motility. In macrophages, IL17D downregulates genes of antigen presentation, as the evidence of the immunomodulatory effects of IL17D, particularly under inflammation. Additionally, the absence of TGF-beta 1 in IL17D knockout fibroblast supernatant unveils a regulatory function of IL17D in cell migration and in the microenvironment of cell migration.

Overall, my study highlights the multifaceted roles of IL17D in cell biology andimmunology, offering insights into its potential as a therapeutic target in cancer and immune diseases. Further research is necessary to unravel the complex mechanisms through which IL17D influences cell behavior and immune responses, which could pave the way for innovative treatments.